Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Nanotechnology ‘can enhance pancreatic cancer drug action’

Nanotechnology ‘can enhance pancreatic cancer drug action’

14th June 2013

A combination of nanoscale biosensors and advanced imaging techniques have been used to enhance methods of treating pancreatic cancer.

Scientists from Australia's Garvan Institute of Medical Research and the UK's Beatson Institute for Cancer Research have utilised nanotechnology to monitor how cancers spread throughout the body and how tumour cells respond to a particular drug.

By monitoring the tiny sensors with fluorescence resonance energy transfer imaging systems, the team was able to see how the small molecule inhibitor dasatinib was able to suppress the signaling protein Src, which becomes activated to drive invasive pancreatic cancer.

Using this method, they could map areas within the tumour that were highly aggressive and pinpoint regions of poor drug delivery.

Professor Kurt Anderson of the Beatson Institute in Glasgow said: "We now have spatial and temporal information about cancer behaviour that we've never had before, as well as the nanotechnology to monitor and improve drug delivery in hard-to-reach tumour regions."

Around 8,000 people are diagnosed with pancreatic cancer in the UK each year, making it the ninth most common cancer type in the country.ADNFCR-8000103-ID-801599019-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.